Ajooni Biotech Limited Board Meeting Approves Increased Authorized Capital and Preferential Issue to Promoters

Ajooni Biotech Limited Board Meeting Approves Increased Authorized Capital and Preferential Issue to Promoters​

Ajooni Biotech Limited, during a Board meeting held on June 29, 2026, announced several strategic corporate decisions, including increasing its authorized share capital and approving a preferential issue of equity shares to persons belonging to the company's promoters. The company also finalized details regarding its upcoming Annual General Meeting (AGM).

The board approved expanding the Authorized Share Capital from Rs. 50,00,00,000/- (Rupees Fifty Crores Only), which was divided into 25,00,00,000 equity shares of Rs. 2/- each, to a new authorized capital of Rs. 70,00,00,000/- (Rupees Seventy Crores Only). This revised capital allows for the issuance of 35,00,00,000 equity shares, retaining a face value of Rs. 2/- each.

In addition to the capital increase, the company sanctioned the issue, offer, and allotment of up to 90,00,000 Equity Shares on a preferential basis. This issuance is directed toward the promoters of Ajooni Biotech Limited. The shares are being issued at an issue price of Rs. 4.30/- per equity share, targeting a total collection amount of Rs. 3,87,00,000/-, with Healthy Biosciences Limited identified as the investor.

AGM Scheduling and Governance Updates​

The Board also approved convening the Annual General Meeting (AGM) on Wednesday, July 29, 2026, which will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

Key scheduling details for the forthcoming AGM include:

• Book closure dates: July 23, 2026 to July 29, 2026.
• Cut off date for member eligibility for remote e-voting and polling at the AGM: Friday, July 17, 2026.

The company’s management decisions regarding governance included appointing M/s. M.R. Chechi & Associates, Practicing Company Secretaries in Chandigarh, as Scrutinizer to oversee the e-voting process during the AGM. Furthermore, the draft director's report for the Financial Year 2025-26 has been prepared for consideration at the AGM.

A decision was also made to defer the proposal concerning the revision or partial modification of Mr. Jasjot Singh’s remuneration as Managing Director, allowing time for further review, while noting that his existing terms will remain in effect until such a subsequent meeting is held.

Shareholding Structure and Preferential Offer Details​

The preferential issue details, which totals 90,00,000 Equity Shares at Rs. 4.30/- per share, are subject to shareholder approval at the AGM. The particulars of the issuance and its impact on the company's shareholding structure have been disclosed as follows:

Preferential Issue Summary:

Promoter and Public Shareholding Status:
The following tables outline the pre and post preferential issue shareholding percentages of the company:

Shareholder Category Pre and Post Preferential Issue:


The issuance will be made to Healthy Biosciences Limited, resulting in the Promoter category increasing from 0.00% pre-issue to 4.97% post-issue, holding a total of 90,00,000 Equity Shares.

AJOONI Stock Price Movement​

Shares of Ajooni Biotech Limited today slipped by 0.54% to settle at ₹3.64 after post-market trading concluded. The equity saw significant activity, with a total traded volume of 217,091 shares during the session.